S
Stellanova Therapeutics
Developing the first cancer therapies targeting cancer-associated fibroblasts (CAFs) and their symbiotic interactions within the tumor microenvironment
About Stellanova Therapeutics
Stellanova Therapeutics, established in 2019, is a Houston-based biotechnology firm operating in the oncology sector. The company was co-founded by Dr. Rosa Hwang, Ronald DePinho, and Emmanuelle Schuler, who also serves as the founding CEO. Stellanova's inception is rooted in the research from Dr. Hwang's lab at MD Anderson Cancer Center. The company's scientific focus is on developing therapies that target the tumor microenvironment, a departure from traditional approaches that focus solely on cancer cells.
The core of Stellanova's strategy is to counteract the pro-tumorigenic effects of carcinoma-associated fibroblasts (CAFs). These cells are known to play a significant role in promoting cancer growth, metastasis, and resistance to therapy. The business operates on a preclinical development model, aiming to advance its discoveries into clinical trials. Its primary client base would eventually be patients with advanced cancers, though its immediate stakeholders are partners in the pharmaceutical and biotech industries. Revenue generation will be contingent on the successful development and commercialization of its therapeutic candidates, likely through partnerships, licensing deals, or acquisition.
Stellanova's lead product candidate is an antibody designed to neutralize DKK3, a factor secreted by CAFs that promotes tumor progression and therapy resistance. This antibody has demonstrated robust anti-tumor activity in preclinical models of treatment-resistant pancreatic and triple-negative breast cancers, particularly when used in conjunction with immune checkpoint inhibitors. The company's platform integrates advanced computational biology and genetic engineering to identify and validate novel targets within the tumor microenvironment. A significant milestone was achieved on June 3, 2021, when Stellanova secured $15.5 million in a Series A financing round led by Sporos Bioventures. This funding was earmarked to advance the lead antibody into first-in-human clinical trials, expand its discovery platform, and grow the team. The company was a resident at JLABS @ TMC, a Johnson & Johnson biotech incubator, and was later acquired by Sporos Bioventures.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2021 | $16M | $62M | Sporos Bioventures | — |
Growth signals
Latest recorded traffic for Stellanova Therapeutics is 250 monthly website visits, up 108.3% over the last three months. Stellanova Therapeutics's team declined 80% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Stellanova Therapeutics in the Houston ecosystem
The Stellanova Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Sporos Bioventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stellanova Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stellanova Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.